Switzerland· 57417031
Neupro 2 mg/24h, dispositif transdermique
A rotigotine product containing rotigotinum, registered in Switzerland by UCB-Pharma SA and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Rotigotine is registered in 18 of 19 countries.
Countries holding a registration under ATC N04BC09 (rotigotine), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 10 of them publish a price we can compare per daily dose
Rotigotine · ATC N04BC09
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rotigotine costs, country by country.
Normalised to the WHO defined daily dose (6 mg), the median price runs from $0.77 in Czechia to $4.34 in Switzerland — a ×5.6 gap.
- Switzerland: $4.34 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Rotigotine · price per daily dose (6 mg)
USD · FX 28 Sept 2026
- CH Switzerland$4.34
- CZ Czechia$0.77
The record
At a glance
Swissmedic (Switzerland)- Active substance
- rotigotinum
- Manufacturer
- UCB-Pharma SA
- Country
- Switzerland (CH)
- ATC code
- N04BC09
- ATC class
- Rotigotine
- Defined daily dose
- 6 mg, TD
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680574170311Btl 28 StkCHF 75.6
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
58 interactions on record for rotigotine.
Graded by severity as the source publishes them — 58 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rotigotine · interactions on record
58 records
- 58 moderate
Most severe, free to view
- MetoclopramideA03FA01moderate
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rotigotine in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomNeupro 1mg/24hours transdermal patchesUCB Pharma Ltd
- CzechiaNEUPROUCB Pharma SA, Brusel
- SpainDARIANTE 1 MG/24 HORAS PARCHES TRANSDÉRMICOS EFGExeltis Healthcare S.L.
- FinlandKinparlevOrion Corporation
- NetherlandsKinparlev 1 mg/24 uur pleister voor transdermaal gebruikOrion Corporation
- BelgiumLegantoUCB
- SwedenKinparlev 1 mg/24 timmar DepotplåsterOrion Corporation
- United StatesNeuproUCB, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 16 EEA countries. Names it is sold under:
- Austria · Kinparlev, Rotigotin Gebro
- Germany · Rotigotin Luye, Rotigotin Neuraxpharm
- Denmark · Kinparlev, Rotigotine Medical Valley
- Spain · Dariante
- Finland · Kinparlev, Rotigotine Medical Valley
- France · Rotigotine Arrow
- Greece · Kinparlev
- Iceland · Neupro, Rotigotine Medical Valley
- Italy · Rotigotina Doc
- Liechtenstein · Neupro
- Luxembourg · Rotigotin Luye
- Netherlands · Rotigotine Medical Valley, Rotigotine Xiromed
- Norway · Kinparlev, Neupro
- Portugal · Kinparlev, Rotigotina Generis
- Romania · Kinparlev
- Sweden · Kinparlev, Rotigotine Medical Valley
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba8ac2e7-a283-46ee-af55-9a115977b362 GET /v1/drugs/ba8ac2e7-a283-46ee-af55-9a115977b362?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "rotigotinum 4.5 mg",
"valid_from": "2018-05-01",
"limitations": "[{\"description\":\"Zur Behandlung von Patienten mit mittelschwerem - schwerem idiopathischem Restless-Legs-Syndrom, wenn die vorgängige Therapie mit oralen Dopamin-Agonisten unzulänglich war. Die Erstverschreibung muss durch einen Neurologen erfolgen.<br>\\nZur Behandlung der idiopathischen Parkinson-Erkrankung.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2018-05-01\"}]",
"galenic_form": "Matrixpfl 2 mg/24h",
"therapeutic_area": null,
"sl_inclusion_date": "2006-12-01",
"self_retention_pct": 10
}See everything about rotigotine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.